Market Overview

Hologic Downgraded By BofA As Cynosure Headwinds Persist

Hologic Downgraded By BofA As Cynosure Headwinds Persist
Related HOLX
Benzinga's Bulls & Bears Of The Week: Amazon, CBS, Intel, Nike, Tesla And More
Benzinga's Top Upgrades, Downgrades For January 4, 2019

An 8-K filed late Wednesday suggests Hologic, Inc. (NASDAQ: HOLX)’s headed for harder times.

The Analyst

Bank of America Merrill Lynch analyst Derik de Bruin downgraded Hologic from Buy to Neutral and cut the price target from $47 to $42.

The Thesis

Hologic subsidiary Cynosure is expected to lose about $15 million in the fourth quarter in forfeited sales and refunds related to its voluntary recall of Vitalia, as well as reduced sales of MonaLisa Touch. The company previously guided for a $7-million Vitalia-related revenue hit.

Nonetheless, Hologic expects strong top-line growth in other core segments to offset the impact to Cynosure. The company reaffirmed revenue guidance between $800 million and $815 million.

Given poor visibility and continued headwinds from Cynosure — coupled with uncertainty around a Quest Diagnostics Inc (NYSE: DGX) contract renewal — Bank of America is withholding its recommendation.

“At this point the fiscal ’19 financial impact of the CYNO recalls and FDA concerns surrounding the VR market are hard to quantify, as it is unclear when HOLX may reintroduce Vitalia or to what extent MLT sales will be reduced,” de Bruin said in a Thursday note. (See his track record here.) 

BofA cut its 2019 bottom-line forecasts from $2.45 to $2.37 to account for lower sales, higher share count and higher interest expense. Hologic’s core business does appear solid, de Bruin said. 

Price Action

Hologic shares were trading 1.18 percent higher at $39.51 at the time of publication Thursday.

Related Links:

WHO Deems The Products Of These Diagnostic Companies 'Essential'

Hologic's SculpSure Body Contouring Treatment Scores Distribution Win

Photo courtesy of Hologic. 

Latest Ratings for HOLX

Jan 2019Cowen & Co.DowngradesOutperformMarket Perform
Jan 2019Morgan StanleyDowngradesEqual-WeightUnderweight
Nov 2018RBC CapitalMaintainsSector PerformSector Perform

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill Lynch Derik de BruinAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (HOLX + DGX)

View Comments and Join the Discussion!

Latest Ratings

PANWBMO CapitalUpgrades240.0
UAAGoldman SachsUpgrades28.0
GPSGoldman SachsDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Coal Exports Face Delays As U.S. East Coast Rail Service Slows For Florence

Finisar, Ciena Downgraded: Why Morgan Stanley Is Turning Neutral On The Optical Companies